



PATIENT

Cinnamon Langis

SPECIES

Canine

BREED

Rat Terrier

SEX

Spayed Female

AGE

11 years

WEIGHT

16.8 lbs.

INTERPRETED BY

R. McKenzie Daniel, DVM,
DABVP (Canine and
Feline)

**IMAGING
PERFORMED BY**

Pamela Harrigan, RDCS

HOSPITAL NAME

Anchor AH

REFERRING VET

Elsa Yeung, DVM

INVOICE

12257

DATE

9/16/21

PRESENTING CLINICAL SIGNS

Frequent urinations since July. Also history UTIs. Previous urine culture negative after receiving medications. Seemed to improve on amoxicillin, but as soon as ended, pollakiuria resumes. LDDS normal in August. BW does not show diabetes, but does show elevated liver enzymes (ALP 690) and platelets (611). Sedated with Butorphanol/Midazolam

Urinary System

A mineralized mass was present in the urinary bladder neck, subjectively primarily involving the dorsal trigone and cystourethral junction. The mass measured approximately 2.3 cm x 1.0 cm. Concurrent, mildly prominent to thickened ventral cystourethral junction wall was present with subjective kissing lesion. Thickened ventral cystourethral junction wall measured up to 0.53 cm width. Mineralization associated with the dorsal mass in the urinary bladder neck was present. The proximal urethra exhibited subjective normal tone to a depth of 2 cm. Primarily anechoic urine was present in the bladder lumen. Moderate, nondependent to swirling, particulate to hypoechoic sediment was present without evidence of calculus formation. The ureteral papillae were normal. The ureters were not visible which is normal.

The area of the aortic trifurcation was free of pathology.

Normal size and margination were present in the kidneys. A normal 1:3 cortex / medulla ratio was maintained. The medulla and cortices were uniform in texture with some increased echogenicity and loss of corticomedullary symmetry and definition expected for the age of the patient. Focal areas of pinpoint medullary mineralization were present in both kidneys. Mild pyelectasia was noted in the right kidney. The left kidney measured 4.4 cm in length. The right kidney measured 5.5 cm in length.

Adrenal Glands

The left adrenal gland was uniform in size and contour with a uniformly hypoechoic parenchyma. The left adrenal gland measured 0.66 cm width at the caudal pole and 0.56 cm width at the cranial pole. The right adrenal gland was uniform in size and contour with a uniformly hypoechoic parenchyma. The right adrenal gland measured 0.53 cm width at the caudal pole and 0.66 cm width at the cranial pole.

Spleen

The spleen exhibited a finely textured and homogenous parenchyma which was hyperechoic to the liver and renal cortical parenchyma. The capsule was smooth and regular without apparent expansion. The splenic vasculature at the hilus was normal in volume with no evidence of congestion or thrombosis. Acute to chronic inflammatory, neoplastic, or benign parenchyma changes were not noted.

Liver/ Gallbladder

The liver presented mildly enlarged in size. The parenchyma of the liver was subjectively normal in echogenicity compared to the spleen and renal cortices. The liver parenchyma was uniform with a mildly coarse echotexture. The capsule of the liver was symmetrically rounded to mildly swollen in margination. The hepatic and portal vasculature were normal in appearance without signs of congestion. The gallbladder was non-distended in size with mild, primarily dependent, nonorganized gallbladder debris. The cystic and common bile ducts were normal.



PATIENT

Cinnamon Langis

SPECIES

Canine

BREED

Rat Terrier

SEX

Spayed Female

AGE

11 years

WEIGHT

16.8 lbs.

INTERPRETED BY

R. McKenzie Daniel, DVM,
DABVP (Canine and
Feline)

**IMAGING
PERFORMED BY**

Pamela Harrigan, RDCS

HOSPITAL NAME

Anchor AH

REFERRING VET

Elsa Yeung, DVM

INVOICE

12257

DATE

9/16/21

Gastrointestinal

The stomach presented intact wall layering with a normal wall layer ratio. The lumen of the stomach was empty with no signs of ileus, obstruction, or foreign material.

The small intestine presented intact wall layering with 1:3 muscularis/mucosa ratio. The lumen of the small intestine was empty with no signs of ileus, obstruction, or foreign material.

Normal visible colon wall layers were present with apparent formed feces in lumen.

Pancreas

The parenchyma of the left limb, body, and right limb of the pancreas presented isoechoic to the adjacent omental fat. A normal curvilinear capsule contour of the pancreas was present. The visible pancreatic duct was normal. No signs of active inflammation or neoplastic disease were evident.

Free Abdomen

No overt evidence of regional metastasis was present.

ULTRASONOGRAPHIC FINDINGS

Primary Findings

- Urinary bladder neck mass
- Bilateral chronic renal changes with pinpoint medullary mineralization and minor right kidney pyelectasia
- Vacuolar hepatopathy pattern
- Mild gallbladder debris (non-mucocele)

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

The urinary bladder neck mass is most consistent with neoplasia with transitional cell carcinoma considered a top differential diagnosis vs. other neoplasia. The possibility of regional significant cystitis is possible yet considered unlikely.

Screening BRAF Assay may be considered. However, if negative, biopsy would be required for a definitive diagnosis. The mass does not appear to be amendable to surgical resection based on location.

The pyelectasia in the right kidney is likely owing to chronic renal changes or potential pelvic scarring owing to previous calculi passage.



PATIENT

Cinnamon Langis

SPECIES

Canine

BREED

Rat Terrier

SEX

Spayed Female

AGE

11 years

WEIGHT

16.8 lbs.

INTERPRETED BY

R. McKenzie Daniel, DVM,
 DABVP (Canine and
 Feline)

IMAGING

PERFORMED BY

Pamela Harrigan, RDCS

HOSPITAL NAME

Anchor AH

REFERRING VET


Elsa Yeung, DVM

INVOICE

12257

DATE


9/16/21



The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Thank you for this referral. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance please contact me.

R. McKenzie Daniel, DVM, DABVP (Canine / Feline Practice)
info@SonoPath.com



PATIENT

Cinnamon Langis

Transitional Cell Carcinoma

<http://www.sonopath.com/TCC>

SPECIES

Canine

BREED

Rat Terrier

SEX

Spayed Female

AGE

11 years

WEIGHT

16.8 lbs.

INTERPRETED BY

R. McKenzie Daniel, DVM,
DABVP (Canine and
Feline)

**IMAGING
PERFORMED BY**

Pamela Harrigan, RDCS

HOSPITAL NAME

Anchor AH

REFERRING VET

Elsa Yeung, DVM

INVOICE

12257

DATE

9/16/21


Description: Many cases of transitional cell carcinoma (TCC) are either mistaken for urinary tract infections (UTIs) or go undiagnosed until they reach an advanced stage, thereby compromising the possibility for successful treatment. In dogs, TCC represents 90-95% of all bladder tumors; the remaining cases are comprised of squamous cell carcinoma, adenocarcinoma, papilloma, leiomyosarcoma, fibrosarcoma, hemangiosarcoma, and rhabdomyosarcoma. Urinary bladder tumors are rare in cats, but when they do occur, they are usually cases of TCC, lymphoma, or mesenchymal tumors.

Clinical Signs: Clinical signs of TCC typically include: hematuria, stranguria, pollakiuria, lethargy, weight loss, and bone pain or organ failure due to metastasis. Diagnosis occurs at a mean age of 11 years, and females are more often affected than males (ratio of 1.7:1). Overrepresented breeds include Scottish Terriers, Shetland Sheepdogs, West Highland White Terriers, Airedale Terriers, and Beagles. Obesity appears to be a predisposing factor. Insecticide exposure as well as cyclophosphamide and acrolein use have also been identified as potential triggers.

Diagnostics: Urine sediment analysis can reveal neoplastic cells in up to 30% of cases; however, interpretation must be scrupulous as reactive cells have a similar morphology to neoplastic ones. Ultrasound diagnostics, when available, provide prompt visualization as well as early detection by capturing minute irregularities in the bladder wall down to 2 mm as well as imaging the pelvic urethra to 3-4 cm caudal from the cystourethral junction. Ultrasound can also be used to evaluate regional lymph nodes and other organs for evidence of metastasis as well as the kidneys and ureter for evidence of impingement and back-pressure from tumors located in the trigone area. One study of 65 dogs suggested that it might be possible to achieve even earlier detection using the veterinary bladder tumor antigen test (V-BTA, Bion Diagnostics), which yielded 90% sensitivity and 78% specificity. False positives occurred, however, in cases where the subjects had hematuria, proteinuria, and glucosuria.

The V-BTA is best used as a screening test, not a diagnostic tool. A negative test suggests that TCC is not likely present, but a positive test indicates that more testing—and a cytopathological or histopathological test in particular—is warranted. Although the V-BTA demonstrates good sensitivity, it only yields reasonable specificity; however, the negative predictive value is 95%. The most appropriate use of this test may be as a screening tool to rule out TCC in geriatric dogs. The second and third generation tests—(BTA stat® and Bard Trak, respectively)—should not be used in dogs as they often yield false negative results.

Treatment: Up to 80% of the urinary bladder can be surgically resected without long-term compromise provided that the trigone is not involved; however, canine TCC often involves the trigone area. TCC in dogs is metastatic, and up to 40% of dogs have metastatic disease at the time of diagnosis (17% of cases will have spread to the lungs). One study of 70 dogs revealed that the 25 that were treated with surgical debulking and medical therapy (chemotherapy and/or piroxicam) achieved a median life span of 272 days. Those that underwent biopsy only with



PATIENT

Cinnamon Langis

medical therapy (42 dogs) experienced a median life span of 195 days, while the remaining 36 dogs that received medical therapy only averaged 150 days.

SPECIES

Canine

Surgical options include partial cystectomy, total cystectomy, ureterocolonic anastomosis, or the insertion of a permanent cystostomy catheter. Complete staging, including 3-view thoracic radiographs and abdominal ultrasound, should be performed prior to surgical intervention. A screening of spinal radiographs allows for an evaluation of the lumbar vertebrae.

BREED

Rat Terrier

Survival times range from a few months to over 48 months, depending on staging criteria and the procedure performed. The survival rate for patients with “non-resectable” trigonal/urethral TCC has improved considerably with the recent development of a new procedure—US-guided endoscopic laser ablation (UGELAB), which can be used in combination with urethral stents. UGELAB has shown significant success as a palliative procedure and can be repeated as progression occurs. Importantly, it avoids seeding by keeping the exfoliating cells within the bladder and is therefore an excellent method of obtaining clean samples given that this kind of tumor is notorious for “trailing” along needle passages. Anecdotal evidence suggests that strongly mineralized tumors respond best to laser ablation (tumor reduction from chemotherapy does not tend to be as effective in these cases). One study of over 60 patients indicated that survival times for those that underwent UGELAB varies depending on the tumor position and ureteral involvement. They ranged between 11 days and 1906 days; however, the median survival time (MST) was approximately 380 days, even in cases when additional therapies had also been pursued.

SEX

Spayed Female

AGE

11 years

WEIGHT

16.8 lbs.

INTERPRETED BY

R. McKenzie Daniel, DVM,
DABVP (Canine and
Feline)

Complete surgical excision of TCC is usually not possible due to trigone location, tumour size, and the presence of multifocal TCC. A study of 67 dogs with TCC resulted in 2 dogs with tumour-free margins; however, one of these dogs experienced a relapse 8 months later, and the other developed metastatic disease. Radiation therapy alone does not appear to be effective, and the benefits of surgical debulking remain controversial. TCC often recurs in the bladder despite surgical resection, either as a result of microscopic disease at the surgical margins or *de novo* tumor growth due to field carcinogenesis. It is thought that TCC may reoccur in other regions of the bladder wall post-resection since it is highly likely that the entire bladder mucosa would have been exposed to the same carcinogen. Previously affected bladders therefore appear to be predisposed to new tumor development.

IMAGING

PERFORMED BY

Pamela Harrigan, RDMS

HOSPITAL NAME

Anchor AH

Chemotherapy remains the treatment of choice for TCC as radiation therapy leads to difficulties with bladder fibrosis. Over the years, various chemotherapeutics have been investigated, such as cisplatin and carboplatin, but few have resulted in increased survivability and many result in significant toxic side effects. Nonsteroidal anti-inflammatory drugs (NSAIDs), including both nonselective COX inhibitors and selective COX II inhibitors, exhibit anti-carcinoma effects and result in partial remission, disease stabilization, and, less commonly, full remission for dogs with TCC. The MST of dogs treated with piroxicam (0.3 mg/kg PO Q24hr) has been reported to be 210 days, which is comparable to the MSTs achieved with other more toxic chemotherapeutics. GI ulceration can occur with piroxicam because it is a non-selective NSAID and inhibits prostaglandin E₂ (PGE₂). To prevent and treat gastric ulceration, misoprostol, a prostaglandin E analogue, should be administered (100 ug/dog PO TID). Selective COX II inhibitors, such as deracoxib (3 mg/kg PO Q24hr) and meloxicam (0.1 mg/kg PO Q24hr), exhibit less GI irritation and can be used

REFERRING VET


Elsa Yeung, DVM

INVOICE

12257

DATE

9/16/21



PATIENT

Cinnamon Langis

SPECIES

Canine

BREED

Rat Terrier

SEX

Spayed Female

AGE

11 years

WEIGHT

16.8 lbs.

INTERPRETED BY

R. McKenzie Daniel, DVM,
DABVP (Canine and
Feline)

**IMAGING
PERFORMED BY**

Pamela Harrigan, RDMS

HOSPITAL NAME

Anchor AH

REFERRING VET

Elsa Yeung, DVM

INVOICE

12257

DATE

9/16/21

as alternatives. Clinical ulceration can be managed with misoprostol (100 ug/dog PO TID), sucralfate (1/2-1 g PO TID; it should be taken one hour before or after food), and concurrent omeprazole (0.7 mg/kg PO Q24hr). One other negative side effect of COX inhibition is reduced renal blood flow due to prostaglandin and thromboxane inhibition, which can result in azotemia in dogs with subnormal renal function. Therefore, it is imperative to assess the baseline renal function and monitor renal analytes over time in these cases.

Piroxicam demonstrates greater therapeutic effectiveness when coupled with other chemotherapeutics, such as mitoxantrone. According to one study, the combination of drugs resulted in an MST of 291 days. Typically, an NSAID is combined with mitoxantrone and/or vinblastine. Current studies are examining the effects of tyrosine kinase inhibitors on TTC and whether it is more effective alone or in combination with piroxicam. Research is also being conducted on the use of metronomic chemotherapy, which entails the long-term administration of a low-dose chemotherapeutic, such as chlorambucil or another agent.

Common complications associated with TCC in dogs include local invasion, which results in urethral and ureteral obstruction and hydronephrosis, and metastatic disease, which leads to systemic involvement. Metastasis most commonly affects local and distant lymph nodes, the lungs, and the liver. Twenty percent of TCC patients present with metastasis at the time of diagnosis.

Urethral obstruction can be treated with an indwelling catheter, intermittent catheterization, or a tube cystotomy; however, the best long-term management entails the insertion of a urethral stent by a specialist trained in Interventional Radiology. Unfortunately, urinary incontinence is a long-term possible complication of stent placement.


Many patients often require concurrent—and recurring—treatment for UTIs. Dogs with TCC may have recurrent or chronic UTIs, and the clinician should therefore remain vigilant with respect to this complicating problem.

Conclusion: TCC is a frequent cause of bladder neoplasia in dogs. Hematuria, pollakiuria, and dysuria are the most common clinical signs. A multimodal therapy that includes NSAIDs, chemotherapy, stent placement, and possibly endoscopic ablation (UGELAB) may extend disease-free intervals for patients. Cats are much less frequently affected by TCC than dogs.

References:

Blackburn AL, Berent AC, Weisse CW, Brown DC. Evaluation of outcome following urethral stent placement for the treatment of obstructive carcinoma of the urethra in dogs: 42 cases (2004-2008). *J Am Vet Med Assoc* 2013;242(1):59-68.

Boria PA, Glickman NW, Schmidt BR, et al. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. *Vet Comp Oncol* 2005;3(2):73-80.



PATIENT

Cinnamon Langis

Cerf DJ, Lindquist EL. Palliative ultrasound-guided endoscopic diode laser ablation of transitional cell carcinomas of the lower urinary tract in dogs. *J Am Vet Med Assoc* 2012;240(1):51-60.

SPECIES

Canine

Glickman LT, Raghavan M, Knapp DW, et al. Herbicide exposure and the risk of transitional cell carcinoma of the urinary bladder in Scottish Terriers. *J Am Vet Med Assoc* 2004;224(8):1290-97.

BREED

Rat Terrier

Henry CJ, Tyler JW, McEntee MC, et al. Evaluation of a bladder tumor antigen test as a screening test for transitional cell carcinoma of the lower urinary tract in dogs. *Am J Vet Res* 2003;64(8):1017-20.

SEX

Spayed Female

Henry CJ. Management of transitional cell carcinoma. *Vet Clin North Am Small Anim Pract* 2003;33(3):597-613.

AGE

11 years

Henry CJ. Bladder and urethral tumors. In: Henry CJ, Higginbotham ML, eds. *Cancer Management in Small Animal Practice*. St. Louis, MO: Elsevier; 2010:290.

WEIGHT

16.8 lbs.

Knapp DW. Urinary bladder cancer. In: Bonagura J, Twedt D, eds. *Kirk's Current Veterinary Therapy XIV*. St. Louis, MO: Saunders Elsevier; 2008:369-73.

Knapp DW. Ultrasound-guided endoscopic diode laser ablation in dogs with transitional cell carcinoma. *J Am Vet Med Assoc* 2012;240(7):802.

INTERPRETED BY

R. McKenzie Daniel, DVM,
DABVP (Canine and
Feline)

London C. Toceranib phosphate for the treatment of solid tumors in dogs and cats. Proceedings from the American College of Veterinary Internal Medicine, Denver, CO, June 15-18, 2011.

IMAGING

PERFORMED BY

Pamela Harrigan, RDCS

McMillan SK, Boria P, Moore GE, et al. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. *J Am Vet Med Assoc* 2011;239(8):1084-89.

HOSPITAL NAME

Anchor AH

Mutsaers AJ, Widmer WR, Knapp DW. Canine transitional cell carcinoma. *J Vet Intern Med* 2003;17(2):136-44.

REFERRING VET

Elsa Yeung, DVM

Nyland TG, Wallack ST, and Wisner ER. Needle-tract implantation following us-guided fine-needle aspiration biopsy of transitional cell carcinoma of the bladder, urethra, and prostate. *Vet Radiol Ultrasound* 2002;43(1):50-53.


INVOICE

12257

Raghavan M, Knapp DW, Dawson MH, et al. Topical flea and tick pesticides and the risk of transitional cell carcinoma of the urinary bladder in Scottish Terriers. *J Am Vet Med Assoc* 2004;225(3):389-94.

DATE

9/16/21



PATIENT

Cinnamon Langis

Schrempp DR, Childress MO, Stewart JC, et al. Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma. *J Am Vet Med Assoc* 2013;242(11):1534-38.

SPECIES

Canine

Weisse C, Berent A, Todd K, et al Evaluation of palliative stenting for management of malignant urethral obstructions in dogs. *J Am Vet Med Assoc* 2006;229(2):226-34.

BREED

Rat Terrier

SEX

Spayed Female

AGE

11 years

WEIGHT

16.8 lbs.

INTERPRETED BY

R. McKenzie Daniel, DVM,
DABVP (Canine and
Feline)

**IMAGING
PERFORMED BY**

Pamela Harrigan, RDMS

HOSPITAL NAME

Anchor AH

REFERRING VET

Elsa Yeung, DVM

INVOICE

12257

DATE

9/16/21